Wall Street brokerages expect BioScrip Inc (NASDAQ:BIOS) to report ($0.11) earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for BioScrip’s earnings, with estimates ranging from ($0.13) to ($0.08). BioScrip reported earnings per share of ($0.16) during the same quarter last year, which would indicate a positive year over year growth rate of 31.3%. The company is scheduled to report its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.21). For the next year, analysts anticipate that the business will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.18) to ($0.14). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow BioScrip.
BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, March 8th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.07). The firm had revenue of $182.50 million for the quarter, compared to analyst estimates of $171.35 million. The business’s revenue for the quarter was down 24.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.06) earnings per share.
A number of equities analysts have recently commented on BIOS shares. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. SunTrust Banks set a $4.00 price objective on shares of BioScrip and gave the company a “buy” rating in a report on Thursday, December 21st. BidaskClub lowered shares of BioScrip from a “buy” rating to a “hold” rating in a report on Friday, March 9th. Craig Hallum reissued a “buy” rating and set a $3.50 price objective on shares of BioScrip in a report on Thursday, March 8th. Finally, Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $3.45.
A number of hedge funds have recently modified their holdings of BIOS. Dynamic Technology Lab Private Ltd purchased a new position in BioScrip during the third quarter valued at approximately $114,000. Gotham Asset Management LLC purchased a new position in BioScrip during the fourth quarter valued at approximately $114,000. Voya Investment Management LLC grew its holdings in BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after purchasing an additional 14,867 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in BioScrip in the third quarter worth $153,000. Finally, MetLife Investment Advisors LLC purchased a new position in BioScrip in the fourth quarter worth $174,000. 84.42% of the stock is currently owned by institutional investors.
Shares of BioScrip (NASDAQ:BIOS) traded up $0.09 during trading hours on Friday, hitting $2.75. 799,786 shares of the stock were exchanged, compared to its average volume of 987,354. The stock has a market capitalization of $344.61, a price-to-earnings ratio of -3.72 and a beta of 0.04. BioScrip has a fifty-two week low of $1.35 and a fifty-two week high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPS” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/zacks-brokerages-expect-bioscrip-inc-bios-to-announce-0-11-eps.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Get a free copy of the Zacks research report on BioScrip (BIOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.